Database Update: Pharmaceutical Drug Production in Russia (December 2017)
Both December and the whole year showed rather disappointing results for Russian pharmaceutical manufacturers. In 2017, Russia produced around 4.5 bln units of pharmaceuticals, which is only 0.7% higher than that in 2016. In monetary terms, the increase is 6.1%, which is still far behind the growth rates in 2015 and 2016. Russian companies put on the market 333.6 bln RUB worth of pharmaceuticals in 2017 (dispatch prices plus VAT).
In December, Russian companies dispatched 31.6 bln RUB worth of pharmaceuticals (dispatch prices plus VAT), with the long-term growth rate amounting to 7% in monetary terms. However, the figures are not particularly interesting because in January, March or August the progress was much higher. In December, the volume of dispatched production in physical terms amounted to as much as 0.41 bln units, while last year it was only in March when we could see the same figures (0.42 bln units). The performance in physical terms is still negative, compared to December 2016 (-5.4%).
Out of the top 20 trademarks, Venarus by OBL Pharm led the way in December 2017, with dispatch volume increasing by 41.6 times over the year. Lantus by Sanofi and Ascorbic acid by Tula Pharm showed the least progress, with dispatch volume decreasing by 49%.
Read more aboutPharmaceutical Drug Production in Russia (November performance) here:http://rncph.com/news/27_12_2017
Dynamics of pharmaceutical drug production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (units) and monetary terms (RUB, including VAT) (January 2016 – December 2017)